PORxin: Additional Phase IIb data

Additional data from the double-blind, Canadian Phase IIb TRIUMPH trial in 92 patients showed that PRX302 non-significantly improved IPSS from baseline to 6 months vs. placebo (8.9 vs. 4.6 points, p=0.0541). PRX302 significantly improved Qmax at day 90 and at 6 months vs. placebo (3.1 and 3.9 mL/second, respectively, vs. 1.3 mL/second for both time points, p=0.0235 and p=0.0258). Patients received 3 µg/mL PRX302 injected into the prostate at a volume equivalent to 20% of the total prostate volume or placebo. Data were presented at the American Urological Association meeting in San Francisco. ...